Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
Open Access
- 14 June 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 4 (1), 29
- https://doi.org/10.1186/1756-8722-4-29
Abstract
Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone secretion may require specific medical interventions to control those symptoms prior to antitumor intervention. In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be required for diagnosis. Other patients may present with more advanced disease, presenting with symptoms of tumor bulk rather than hormone secretion. Treatment options for patients with advanced pancreatic neuroendocrine tumors include surgical resection and hepatic directed therapies, including partial hepatectomy, hepatic artery embolization, or other ablative techniques. Streptozocin or temozolomide-based chemotherapy regimens are active against pancreatic NET, and can also play an important role in the palliation of patients with advanced disease. A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways have recently shown promise, with recent trials showing treatment with the VEGFR tyrosine kinase inhibitor sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.Keywords
This publication has 62 references indexed in Scilit:
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 2008
- Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine TumorsGastroenterology, 2008
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Surgery Increases Survival in Patients With GastrinomaAnnals of Surgery, 2006
- Use of omeprazole in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1991
- Omeprazole in Zollinger–Ellison SyndromeThe New England Journal of Medicine, 1984